Nasus Pharma

Nasus Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nasus Pharma (NSRX) as of Oct 25, 2026 is -4.90 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.08 M USD — a change of 354.92% (lower).

EBITDA

-4.90 MUSD

YoY

354.92%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nasus Pharma is 2025 -4.90 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nasus Pharma was 2024 -1.08 M USD. It decreases by 354.92% lower compared to the previous year.

The Nasus Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
-2.04 M USD
Jan 1, 2023
-1.15 M USD
Jan 1, 2024
-1.08 M USD
Jan 1, 2025
-4.90 M USD
The Nasus Pharma EBITDA history
YEAREBITDAYoY
-4.90 MUSD+354.92%
-1.08 MUSD-6.02%
-1.15 MUSD-43.83%
-2.04 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nasus Pharma Stock analysis

What does Nasus Pharma do? Nasus Pharma Ltd is an Israel-based pharmaceutical company specializing in microsphere technology for intranasal powder-based drug delivery systems. The firm manufactures pharmaceutical preparations designed for rapid, non-invasive administration of medications targeting conditions like anaphylaxis and opioid overdose. Their products focus on fast absorption, ease of use, and effectiveness in emergency scenarios, enabling caregivers, non-professionals, and medical professionals to administer life-saving treatments without specialized training. Nasus Pharma Ltd's formulations aim to improve access to critical medications by simplifying administration in urgent situations. The company's primary products are intranasal powder-based drug delivery systems utilizing microsphere technology. These systems are tailored for conditions requiring immediate intervention, such as anaphylaxis and opioid overdose. The firm targets medical doctors, emergency nurses, and caregivers as key buyers, emphasizing the products' role in critical care settings where speed and simplicity are essential. Nasus Pharma Ltd positions itself as a provider of accessible emergency treatments that bridge gaps in traditional medical administration. Nasus Pharma Ltd's business model centers on developing and commercializing pharmaceutical preparations that leverage microsphere technology for intranasal delivery. The company focuses on creating solutions for life-saving treatments that can be administered by non-specialists, thereby expanding the reach of critical medications. By addressing the need for rapid, non-invasive drug delivery in emergencies, Nasus Pharma Ltd caters to healthcare providers and emergency responders who require reliable, easy-to-use products during critical incidents. Nasus Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nasus Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nasus Pharma is -4.90 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nasus Pharma changed from -1.08 M USD to -4.90 M USD, representing a 354.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Nasus Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Nasus Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Nasus Pharma

All Key Metrics — Nasus Pharma